Based on these reports, we believe that the potential of MCP compounds to enhance the efficacy and mitigate the side effects of conventional anti-cancer therapies, such as chemotherapeutic agents' activation (e.g., paclitaxel48 and gemcitabine12), targeted growth factor inhibitors (e.g., STAT348 and BSG), and radiation therapy,49 is highly significant. The gene discussed is BSG; the disease is cancer.